TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33630393
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g)
Study: 32810921
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioural therapy for insomnia (Sleepio)
Study: 34551104
Drug: Middle-dose vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose vaccine
Study: 34551104
Drug: Ad5-vectored COVID-19
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored COVID-19 vaccine (single dose in children and adolescents)
Study: 34551104
Drug: Ad5-vectored COVID-19
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored COVID-19 vaccine (two doses in adults)
Study: 34287975
Drug: Fractional RF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional RF treatment with 1.0‐mm long × 0.15‐mm diameter ultrathin electrode tips
Study: 32844454
Drug: Lanolin-containing test
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin-containing test creams applied twice daily for 4 weeks on arms with irritant dermatitis
Study: 32844454
Drug: Lanolin-free cream
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin-free cream base applied twice daily for 4 weeks on arms with irritant dermatitis
Study: 35276700
Drug: Graded exposure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exposure treatment (GET)
Study: 34051122
Drug: Tapentadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (50 mg twice daily)
Study: 34051122
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg twice daily)
Study: 33444780
Drug: Optimised adherence
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised adherence treatment (post-programme)
Study: 36251383
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg·kg ‐1 body weight)
Study: 34037271
Drug: RO7062931 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7062931 at 3.0 mg/kg every week (QW)
Study: 34037271
Drug: RO7062931 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7062931 at 0.5, 1.5, or 3.0 mg/kg every month for a total of 2 doses
Study: 34037271
Drug: RO7062931 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7062931 at 3.0 mg/kg every 2 weeks, 3.0 mg/kg every week (QW), or 4.0 mg/kg QW
Study: 36027721
Drug: idursulfase-IT 10
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: idursulfase-IT 10 mg
Study: 33811746
Drug: First-line platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum-based chemotherapy (carboplatin/paclitaxel)
Study: 32150263
Drug: D0 rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: D0 rituximab infusion (500 mg)
Study: 32150263
Drug: D0+D14 rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: D0+D14 rituximab infusion (500 mg)
Study: 35144885
Drug: Oral trimethoprim-sulfamethoxazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole, twice daily for 10 days postoperatively
Study: 35144885
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 10 days postoperatively
Study: 35144885
Drug: Oral trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole
Study: 33002436
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg)
Study: 33002436
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus trastuzumab emtansine (3.6 mg/kg)
Study: 36149321
Drug: Miconazole buccal
Normalized name: miconazole Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole buccal tablets (MBT) plus placebo
Study: 36149321
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules plus placebo
Study: 35840067
Drug: Amniotic suspension
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic suspension allograft (ASA)
Study: 35051670
Drug: Sleep study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep study screening with autoregulated positive airway therapy
Study: 35406010
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1200 IU/day) + DHA (500 mg)
Study: 34620658
Drug: Bevacizumab-800CW (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-800CW (4, 5, 10 or 25 mg)
Study: 33619202
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics alone (n=15)
Study: 33619202
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics and immediate cranberry capsules for up to 7 days (n=15)
Study: 33619202
Drug: Immediate cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cranberry capsules and delayed antibiotics for self-initiation in case of non-improvement or worsening of symptoms (n=16)
Study: 35243872
Drug: Standard-treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-treatment group
Study: 34291590
Drug: Rivastigmine (3–6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3–6 mg twice a day)
Study: 35584331
Drug: 10% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% NaOCl solution (deproteinization)
Study: 35584331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acid etching with 37% phosphoric acid + placebo solution + Adper Single Bond 2/3M Oral Care + Filtek Z350/3M Oral Care)
Study: 35220503
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (FOLFOX or CAPOX)
Study: 37028940
Drug: Pirfenidone (2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (2403 mg/day)
Study: 32603714
Drug: Evening long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening long‐acting bronchodilation (aclidinium bromide/formoterol fumarate dihydrate: 400/12 μg)
Study: 32603714
Drug: Evening long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening long‐acting bronchodilator (aclidinium bromide/formoterol fumarate dihydrate: 400/12 μg)
Study: 32429917
Drug: Healthy food
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy food nudges (e.g., product placement or promotion)
Study: 34034821
Drug: Delayed Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed Intervention (DI) group - given contact information for a nearby addiction medicine clinic.
Study: 36181412
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus FMT therapy
Study: 36181412
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus FMT therapy with 3 administrations
Study: 36181412
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus FMT therapy with 6 administrations
Study: 32111579
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS over the left PFC (1.5 mA, 5-cm x 5-cm electrodes) with concurrent cathodal tDCS over the right PFC during emotion regulation task.
Study: 34078591
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg immediately after the surgical procedure, and on day 1)
Study: 36418131
Drug: Clinically assisted
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically assisted hydration (CAH) - parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Study: 33822650
Drug: Intensified clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified clinical pharmacological/pharmaceutical care (medication management and structured patient counseling) over 12 weeks
Study: 33822650
Drug: Intensified clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified clinical pharmacological/pharmaceutical care (intervention group)
Study: 33942777
Drug: ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine + dexmedetomidine (1 μg/kg)
Study: 33942777
Drug: ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine + fentanyl (1 μg/kg)
Study: 33942777
Drug: ropivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine (40 mL/0.5%)
Study: 33168838
Drug: Amylase quantification
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylase quantification in the terminal ileum; daily analysis of ileostomy effluent for the first 5 post-operative days.
Study: 34348529
Drug: Higher genetically
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher genetically predicted IL-1 receptor antagonist (IL-1Ra)
Study: 34883506
Drug: Clofarabine (CLO)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (CLO) added to induction and consolidation treatment
Study: 35442223
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based regimen
Study: 33772746
Drug: 131I therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I therapy for low-risk DTC patients
Study: 33772746
Drug: 131I therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I therapy for low-risk papillary thyroid microcarcinomas
Study: 33687578
Drug: sCT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT treatment
Study: 33615951
Drug: Daily synbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily synbiotic supplement (5 g prebiotic fiber + 8 billion CFU probiotic B. lactis) with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Study: 33615951
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Study: 32048788
Drug: 1 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 session per week of acupuncture (group L)
Study: 34471000
Drug: curcuRougeTM (newly
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcuRougeTM (newly developed highly bioavailable curcumin formulation) administered for 4 weeks
Study: 33050760
Drug: Peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 100 mg/day
Study: 33050760
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg/day
Study: 33050760
Drug: Peficitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (all doses)
Study: 33434399
Drug: DAV132 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAV132 7.5 g administered concomitantly with warfarin (5 mg) and clonazepam (1 mg)
Study: 33434399
Drug: DAV132 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAV132 7.5 g administered 1 hour before warfarin (5 mg) and clonazepam (1 mg)
Study: 35299753
Drug: Supervised resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised resistance training for 12 weeks during adjuvant chemotherapy
Study: 36216140
Drug: rs53576 G
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs53576 G homozygotes in the neuroimaging arm
Study: 33975171
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or Paroxetine
Study: 37779358
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus intensive lifestyle therapy
Study: 37779358
Drug: Conventional lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lifestyle therapy with placebo
Study: 37779358
Drug: Intensified lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified lifestyle therapy, pioglitazone, or their combination
Study: 33836215
Drug: Larger portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger portion of vegetables (120 g)
Study: 33887408
Drug: MF-PRP HD
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-PRP HD (High Dose)
Study: 33887408
Drug: MF-PRP LD
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-PRP LD (Low Dose)
Study: 34953401
Drug: Intravenous 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq over 4 h pre-cisplatin 40 mg/m2 weekly for 7-8 weeks (Control group)
Study: 34953401
Drug: Intravenous 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq + additional 16 mEq magnesium (Mg group)
Study: 34210061
Drug: Ontario Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontario Brain Injury Association Peer Support Program (weekly intervention)
Study: 32531259
Drug: Sofosbuvir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (200 mg) plus ribavirin (200 mg) for 24 weeks
Study: 32531259
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) plus ribavirin (200 mg) for 24 weeks
Study: 32531259
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) plus sofosbuvir (400 mg) for 12 weeks
Study: 33781269
Drug: CAF-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-3 (3 mg/kg/b.m.)
Study: 33781269
Drug: CAF-6 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-6 (6 mg/kg/b.m.)
Study: 36014925
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration for 12 weeks
Study: 33103603
Drug: Glucagon bolus
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon bolus (50 µg/kg)
Study: 33103603
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion (50 µg/kg)
Study: 33103603
Drug: Esmolol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.25 mg/kg bolus + 0.75 mg/kg/min infusion)
Study: 32209625
Drug: G-CSF (filgrastim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (filgrastim)
Study: 32209625
Drug: Placebo (indistinguishable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (indistinguishable glucose solution 5%)
Study: 36375780
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ferric carboxymaltose (FCM)
Study: 36375780
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL of physiological serum)
Study: 35364413
Drug: Transcutaneous vagal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous vagal nerve stimulation (tVNS) - early stimulation (4 hours daily between Day 0 and 13)
Study: 35364413
Drug: Transcutaneous vagal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous vagal nerve stimulation (tVNS) - late stimulation (4 hours daily between Day 14 and 28)
Study: 33249449
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and tDCS
Study: 33249449
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and sham tDCS
Study: 35213547
Drug: Sarilumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab, 200 or 400 mg subcutaneous injection
Study: 36476193
Drug: Spirulina (SP)
DrugBank: Spirulina platensis (DB14744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (SP) 2 g per day for 5 weeks
Study: 33904798
Drug: 1-day antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day antibiotics (ciprofloxacin)
Study: 33904798
Drug: 3-day antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day antibiotics (ciprofloxacin)
Study: 35340172
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody combined with total neoadjuvant chemoradiotherapy
Study: 34511134
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Study: 34511134
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W plus statin
Study: 34843806
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexamethasone with 0.5% ropivacaine and 0.2% lignocaine
Study: 35971069
Drug: Step function
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step function model fitted on data from all treatment arms
Study: 36399083
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to self-selected music for 30 minutes daily for two weeks (Multi-Music Group - MG)
Study: 36399083
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to lullabies for 30 minutes daily for two weeks (Lullaby Group - LG)
Study: 36048417
Drug: Ad5‐nCoV (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5‐nCoV (5 × 10^10 viral particles/vial, 0.5 mL)
Study: 33569869
Drug: Adventure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adventure therapy (AT)
Study: 33569869
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (based on cognitive-behavioral therapy)
Study: 35367469
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure at concentrations of 20, 50, and 150 μg/m3 for 4 hours
Study: 35367469
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure at concentrations of 50 μg/m3 and above
Study: 32372407
Drug: Post-foaming dental
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-foaming dental gel (Group 1: device-enhanced; Group 2: toothbrush)
Study: 32372407
Drug: Post-foaming dental
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-foaming dental gel (Group 1: device-enhanced)
Study: 32372407
Drug: Post-foaming dental
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-foaming dental gel (Group 2: toothbrush)
Study: 32372407
Drug: Post-foaming dental
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-foaming dental gel (Group 1 and 2)
Study: 34268908
Drug: Hydroxychloroquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine with pantoprazole (40 mg once daily for 9 days)
Study: 32460589
Drug: G. sylvestre
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. sylvestre 300 mg b.i.d.
Study: 35503591
Drug: 4 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 hourly rotation of masks and prongs
Study: 34853089
Drug: Ustekinumab (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (approximately 6 mg/kg single intravenous infusion, then subcutaneous injections of 90 mg every 8 weeks)
Study: 32880201
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (RJ) supplementation (3000 mg of fresh RJ equivalent)
Study: 33906810
Drug: MR‐proADM guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR‐proADM guided arm (low MR‐proADM value ≤0.87 nmol/L)
Study: 33906810
Drug: MR‐proADM guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR‐proADM guided arm (high MR‐proADM value >0.87 nmol/L)
Study: 34416193
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine (two doses, 28 days apart)
Study: 32969200
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (n=12) received mesalazine (60 mg kg−1 day−1) and oral probiotics (Lactobacillus casei Zhang, Lactobacillus plantarum P‐8, Bifidobacterium animalis subsp. lactis V9) twice daily for 12 weeks
Study: 33296553
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound (LIPUS) administered twice weekly for 24 weeks
Study: 35892316
Drug: Atrasentan (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan (dosage not specified)
Study: 32466858
Drug: Senofilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senofilcon A lenses with polyquaternium-based care solution (OPTI-FREE Replenish)
Study: 35267097
Drug: 1.4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 ml 2% lidocaine + 0.4 ml (40 μg) dexmedetomidine (DEX)
Study: 35267097
Drug: 1.4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 ml 2% plain lidocaine
Study: 34429952
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid (TXA) 500mg/5 mL, total 10 mL at the surgical site.
Study: 33884617
Drug: Mentalisation-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalisation-based therapy (MBT)
Study: 34710071
Drug: Pericoital tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pericoital tenofovir 1% gel